Auragin

Auragin is a stealth-mode biotechnology company focused on developing a new class of regenerative medicines for cardiovascular diseases. The company's core technology utilizes modified messenger RNA (modRNA) to induce the regeneration of heart tissue following injury, such as a myocardial infarction. By delivering specific genetic instructions directly to the heart, Auragin aims to stimulate the proliferation of cardiomyocytes and improve cardiac function. Founded by leading experts in RNA biology and cardiology, the company is currently advancing its proprietary platform through pre-clinical development to address significant unmet needs in heart failure and ischemic heart disease.